Actelion Pharmaceuticals US, Inc.
Actelion Pharmaceuticals US, Inc. received $768K in federal prime contract obligations in the 12 months ending Oct 5, 2026, down 43.3% from $1.4M the year before, and $10.0M since FY2022. Its largest customer is the Department of Veterans Affairs.
Contractor details
- Unique Entity ID (UEI)
- H5BMHLMMNA28
- CAGE code
- 33TN9
- Headquarters
- South SAN Francisco, CA
- Business size
- Other Than Small Business
- Parent company
- Johnson & Johnson Healthcare (UEI LKV3QN1ND7D1)
As recorded on this UEI's most recent prime contract action in USAspending.gov. Confirm current registration and certifications in SAM.gov.
Obligations by fiscal year
Net prime contract obligations by federal fiscal year.
Markets where it ranks top 10
Agency and NAICS markets where this UEI is one of the ten largest primes in the latest 12 months.
Top agencies
Funding agencies ranked by obligations since FY2022.
| Funding agency | Latest 12 mo | Since FY2022 |
|---|---|---|
| Department of Veterans Affairs | −$207K | $7.4M |
| Department of Justice | $975K | $2.6M |
Top NAICS codes
Industry codes agencies recorded on this contractor's awards, since FY2022.
| NAICS | Industry | Latest 12 mo | Since FY2022 |
|---|---|---|---|
| 325412 | Pharmaceutical Preparation Manufacturing | $768K | $10.0M |
What it sells
Product and service codes (PSC) on this contractor's awards, since FY2022.
| PSC | Description | Since FY2022 |
|---|---|---|
| 6505 | Drugs and Biologicals | $8.3M |
| Q517 | Pharmacy Services | $1.7M |
Recent awards
This contractor's newest prime contract awards, most recent first.
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| 15B50926F00000155 | Department of Justice FY26-PHARMACY MARCH | $62K | Aug 10, 2026 |
| 15B50926F00000148 | Department of Justice FY26-PHARMACY ACTELION (UPTRAVI/OPSUMIT) FEBRUARY | $62K | Jul 28, 2026 |
| 15B50526F00000184 | Department of Justice CURASCRIPT, (1)UPTRAVI 200MCG 140 TAB+800MCGX60TB TT PK (1)UPTRAVI 200MCG TAB 60/BTL+(3)UPTRAVI 200MCG TAB 60/BTL | $95K | Jul 15, 2026 |
| 15B50526F00000181 | Department of Justice VELETRI 1.5MG SDV JULYAUGUST/SEPTEMBER FY26 | $19K | Jul 9, 2026 |
| 15B50526F00000169 | Department of Justice OPSUMIT 10MG-QTY 3 @ $12,853.56 MAY ORDER HOME CONFINEMENT 90 DAYS' SUPPLY | $39K | Jun 3, 2026 |
| 15B50926F00000100 | Department of Justice FY26-PHARMACY ACTELION (UPTRAVI/OPSUMIT) SEPTEMBER | $62K | Apr 23, 2026 |
| 15B50926F00000097 | Department of Justice FY26-PHARMACY ACTELION (UPTRAVI/OPSUMIT) JUNE | $62K | Apr 23, 2026 |
| 15B50926F00000098 | Department of Justice FY26-PHARMACY ACTELION (UPTRAVI/OPSUMIT) JULY | $62K | Apr 23, 2026 |
Other Johnson & Johnson Healthcare entities
UEIs that report the same ultimate parent in SAM.gov. Ownership records can lag acquisitions.
Prime contracts (award types A–D) from USAspending.gov through Oct 5, 2026. Subcontracts are not included. Net obligations include deobligations and corrections.
Ready to connect your pursuit work?
GovEagle gives BD directors, capture managers, and proposal teams one AI workspace from pipeline through proposal, with CMMC/FedRAMP Certified compliance built in.